Rapport Therapeutics, Inc. (RAPP)

NGM – Real vaqt narxi. Valyuta: USD

47.87

-0.95 (-1.96%)

Bozor ochiq: Aug 12, 2026, 1:28 PM EDT

49.78

+0.96 (1.97%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

05.08.2026

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending June 30, 2026, and highlighted continued progress across the RAP-219 development program and pipeline. "We remain focused on disciplined execution as we deliver against several important catalysts this year," said Abraham N.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
RAPP	William Blair	Outperform	undefined >> undefined	July 28th 2026

Press-relizlar

05.08.2026

Rapport Therapeutics, Inc. (RAPP)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Search stocks

Rapport Therapeutics, Inc. (RAPP)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update